Login
ANSTO extends partnership with ITM
The Australian Nuclear Science and Technology Organisation has secured a long-term IP and technology license agreement with a Germany-based company.
Naomi Neilson
Firm: Maddocks (ANSTO)
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: Maddocks has advised the Australian Nuclear Science and Technology Organisation (ANSTO) on a new long-term IP and technology license agreement with leading German radiopharmaceutical biotech company ITM Isotope Technologies Munich SE.
Value: N/A
Area: IP
Key players: The team was led by IP and life sciences partner Ben Miller, who was assisted by lawyer Sophie Vo and the firms’ IP and pharma regulatory team.
Deal significance: The continuation of ANSTO’s longstanding partnership with ITM is significant as it allows local manufacturing to continue to support the growing demands of patients in the Australia-New Zealand region.
